Benchmarking helps organisations examine how their pharmacovigilance system performs and where improvement would be most valuable. These questions cover assessment methods, comparisons, evidence and the use of findings in operational and strategic decisions.
An audit generally evaluates activities against defined criteria through a planned, systematic examination. Benchmarking focuses on comparison, which may include performance, capability and maturity against selected reference points.
There can be overlap in the evidence reviewed. However, a benchmarking exercise should not be assumed to replace an audit or other required assurance activity. Its purpose and limitations should be explicit.
Compliance concerns whether applicable obligations are met. Maturity describes how consistently and effectively a system is organised, managed and improved against a defined framework.
A maturity assessment can identify opportunities beyond minimum requirements, but a high score does not establish compliance by itself. Pharmacovigilance Benchmarking should distinguish these concepts when presenting findings.
The scope can cover governance, operational processes, quality controls, partner oversight, resources, training and performance measurement. It may examine the whole system or selected areas.
Choose the scope according to the questions you need answered. An assessment intended to support a sourcing decision may require different evidence from one focused on consistency across regional teams.
No. An industry average may be difficult to interpret if the underlying organisations have different responsibilities, products, workloads or reporting methods.
Before using an external comparison, ask how the data was obtained and whether it is genuinely comparable. Where a meaningful comparison is unavailable, a transparent assessment against defined criteria may be more useful than an unsupported industry ranking.
Use clear assessment criteria, consistent evidence requirements and documented reasoning. Identify assumptions and allow factual findings to be checked without obscuring material concerns.
It is also useful to distinguish observed evidence from assessor judgement. Where scoring is used, the method should explain what each level means and how conclusions were reached.
Yes, provided the scope and available evidence support it. The assessment can examine the organisation’s oversight arrangements, service interfaces and relevant performance information.
Access to provider information may need to be agreed in advance. Findings about outsourcing arrangements can inform Pharmacovigilance Management Consulting, particularly where governance or responsibilities need improvement.
Review the supporting evidence and distinguish factual disagreement from differences in interpretation or risk tolerance. Additional information may resolve the issue or change the assessment.
If a material disagreement remains, document it transparently alongside the reasoning for the final conclusion. This is more useful than forcing apparent agreement without addressing the underlying concern.
It can identify strengths, gaps and areas requiring further preparation. It may also help assess whether oversight and supporting evidence are sufficiently developed within the reviewed scope.
It cannot guarantee an inspection outcome. Inspection readiness depends on the wider system, current practice and the evidence available at the time of inspection, including areas outside the assessment.
Leadership can use findings to prioritise investment, assign improvement ownership and challenge whether current arrangements remain suitable. The report should explain the significance of gaps and the consequences of leaving them unresolved.
Within a wider Pharmacovigilance Consulting engagement, findings can help organise a realistic programme of change rather than a disconnected list of recommendations.
First determine whether the gap concerns knowledge, practical skill, unclear responsibility or a process weakness. The response should match the cause.
Where learning is needed, Pharmacovigilance Training can support targeted development. Combine this with changes to documentation, supervision or workflow where those factors also affect performance.
Assess your current position
Explore Qinecsa’s Pharmacovigilance Benchmarking service to discuss an assessment aligned with your organisation’s priorities and decision-making needs.